This study is testing a treatment called obecabtagene autoleucel (obe-cel) for people with newly diagnosed, high-risk B-cell acute lymphocytic leukemia (ALL). Obecabtagene autoleucel is a type of immunotherapy called CAR-T, which uses your own modified immune cells to fight cancer. The goal is to see if obe-cel, given after initial treatment (consolidation therapy), can help control the leukemia. Researchers will be looking at how safe the treatment is and how well it prevents the leukemia from coming back. You might be able to join if you are 18 or older, have high-risk B-cell ALL in first remission, and meet specific genetic criteria like KMT2A rearranged ALL or Philadelphia-like ALL. The study plans to enroll 30 participants.

Study design

This is an interventional study with a planned enrollment of 30 participants. It is a Phase 2 study, meaning it's evaluating the treatment's effectiveness and safety in a larger group of people.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your safety and side effects will be monitored through study completion, which is an average of 1 year. The study also aims to assess how long you remain free of leukemia for 18 months and your overall survival for 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.